Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells

Anti-Cancer Drug Design

Volumn 13, Issue 5, 1998, Pages 489-499

  Distefano, M ^a   Scambia, G ^a   Ferlini, C ^a   Gallo, D ^a   De Vincenzo, R ^a   Filippini, P ^a   Riva, A ^b   Bombardelli, E ^b   Mancuso, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b INDENA S P A   (Italy)

Author keywords

Antitumor activity; MDR phenotype; Paclitaxel analogues

Indexed keywords

DNA FRAGMENT; DOCETAXEL; PACLITAXEL; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOSIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE; CELL SURVIVAL; DNA FRAGMENTATION; DRUG RESISTANCE, MULTIPLE; GENES, MDR; HUMANS; PACLITAXEL; PHENOTYPE; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0031828267     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. APPENDING, G., JAKUPOVIC, J., VARESE, M., BELLORO, E., DANIELI, B. & BOMBARDELLI, E. (1996). Synthesis of 7,9-nitrogen-substituted paclitaxel derivatives. Tetrahedron Letters, 37, 7837.
2. APPENDINO, G., DANIELI, B., JAKUPOVIV, J., BELLORO, E., SCAMBIA, G. & BOMBARDELLI, E. (1997). Synthesis and evaluation of C-seco paclitaxel analogues. Tetrahedron Letters, 38, 4273.
3. BHALLA, K., HUANG, Y., TANG, C., SELF, S., RAY. S., MAHONEY, M.E., PONNATHPUR, V., TOURKJNA, E., IBRADO, A.M., BULLOCK, G. & WILLINGHAM, M.C. (1994). Characterisation of a human myeloid leukemia cell line highly resistant to taxol. Leukemia, 8, 465.
4. DANCEY, J. & EISENHAUER, E.A. (1996). Current perspectives on camptothecins in cancer treatment. British Journal of Cancer, 74, 327.
5. DARZYNKIEWICZ, Z., BRUNO, S., DEL BINO, G., GORCZYCA,W., HOTZ, M. A., LASSOTA, P. & TRAGANOS, F. (1992). Features of apoptotic cells measured by flow cytometry. Cytometry, 13, 795.
6. DISTEFANO, M., SCAMBIA, G., FERLINI, C., GAGGINI, C., DE VINCENZO, R., RIVA, A., BOMBARDELLI, E., OJIMA, I., FATTOROSSI, A., BENEDETTI PANICI, P. & MANCUSO, S. (1997). Anti-proliferativc activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance- positive human cancer cells. International Journal of Cancer 72, 844.
7. FERLINI, C., DI CESARE, S., RAINALDI, G., MALORNI, W., SAMOGGIA, P., BISELLI, R. & FATTOROSSI, A. (1996). A flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry, 24, 106.
8. FERLINI, C., SCAMBIA, G., DISTEFANO, M., FILIPPINI, P., ISOLA, G., RIVA, A., BOMBARDELLI, E., FATTOROSSI, A., BENEDETTI PANICI, P. & MANCUSO, S. (1997). Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. British Journal of Cancer, 75, 884.
9. FUMOLEAU, P., CHEVALLIER, B., KERBRAT, P., DIERAS, V., AZLI, N., BAYSSAS, M. & VON GLOBBEKE, M. (1994). Current status of taxotere (docetaxel) as a new treatment in breast cancer. Breast Cancer Research Treatment, 33, 39.
10. HORWITZ, S.B., LOTHSTEIN, L., MANFREDI, J.J., MELLADO, W., PARNESS, J., ROY, S.N., SCHIFF, P.B., SORBARA, L. & ZEHEB, R. (1986). Taxol: mechanisms of action and resistance. Annals of the New York Academy of Science, 466, 733.
11. JORDAN, M.A., WENDELL, K., GARDINER, S., DERRY, B., COPP, H. & WILSON, L. (1996). Mitotic block induced in HeLa cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Research, 56, 816.
12. MCGUIRE, W.P., ROWINSKY, E.K., ROSENSHEIM, N.B., GRUMBINE, F.C., ETTINGER, D.S., ARMSTRONG, D.K. & DONEHOWER, R.C. (1989). Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal Medicine, 111, 273.
13. MCGUIRE, W.P., HOSKINS, W.J., BRADY, M.F., KUCERA, P.R., PARTRIDGE, E.E., LOOK, K.Y, CLARKE-PEARSON, D.L. & DAVIDSON, M. (1996). Ciclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine, 334, 1.
14. NYGREN, P., CSOKA, K., JONSSON, B., FREDBORG, H., BERGH., J., HAGBERG, H., GLIMELINS, B., BRODEN, O., THOLANDER, B., KRENGER, A., LONNERHOLM, G., JAKOBSSON, L.A., OLSEN, J., KRISTENSEN, J. & LARSSON, F. (1995). The cytotoxic activity of taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. British Journal of Cancer, 71, 478.
15. OJIMA, I., SLATER, J.C., MICHAUD, E., KUDUK, S.D., BOUNAUD, P.Y, VRIGNAUD, P., BISSERY, M.C., VEITH, J. M., PERA, P & BERNACKI, R.J (1996). Synthesis and structure-activity relationships of the second- generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. Journal of Medicinal Chemistry, 39, 3889.
16. O'SHAUGHNESSY, J.A. & COWAN, K.H. (1994). Current status of paclitaxel in the treatment of breast cancer. Breast Cancer Research and Treatment, 33, 27.
17. ROWINSKY, E.K., CAZENAVE, L.A. & DONEHOWER, R.C. (1990). Taxol: a novel investigational anti- microtubule agent. Journal of the National Cancer Institute, 82, 1247.
18. SCAMBIA. G., RANELLETTI, F.O., BENEDETTI PANICI, P., PIANTELLI, M., BONANNO, G., DE VINCENZO, R., FERRANDINA, G., PIERELLI, L., CAPELLI, A. & MANCUSO, S. (1991). Quercetin inhibits the growth of a multidrug-resistant estrogen receptor negative MCF-7 human breast cancer cell line expressing type II estrogen binding sites. Cancer Chemotherapy and Pharmacology, 28, 255.
19. SCAMBIA, G., RANELLETTI, F.O., BENEDETTI PANICI, P., DE VINCENZO, R., BONANNO, G., FERRANDINA, G., PIANTELLI, M., BUSSA. S., RUMI, C., CIANFRIGLIA, P. & MANCUSO, S. (1994). Quercetin potentiates the effect of adriamycin in a mutlidrug resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target. Cancer Chemotherapy and Pharmacology , 94, 459.
20. SEIDMAN, A.D., REICHMAN, B.S., CROWN, J.P.A., YAO. T.J., CURRIE, V., HAKES, T.B., HUDIS, C.A., GILEWSKI, T.A., BASELGA, J., FORSYTE, P., LEPORE, J., MARKS, L., FAIN, K., SOUHRADA, M., ONETTO, N., ARBUCK, S. & NORTON, L. (1995). Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracyclin response. Journal of Clinical Oncology, 13, 1152.
21. VASEY, P.A., JONES, N.A., JENKINS, S., DIVE, C. & BROWN, R (1996). Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Molecular Pharmacololgy, 50, 1536.
22. WAHL, A.F., DONALDSON, K.L., FAIRCHILD, C., LEE, F.Y.F., FOSTER, S.A., DEMERS, W. & GALLOWAY, D.A. (1996). LOSS of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Medicine, 2, 72.